[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 12, 1957


JAMA. 1957;165(6):688-689. doi:10.1001/jama.1957.02980240046015

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Elsewhere in this issue of The Journal (page 657) is a thought-provoking article that undoubtedly will interest both physicians and drug manufacturers. It points to problems obviously disturbing to the author and presumably also to some of his colleagues. However, there are statements in the article that may cause confusion, even consternation, if they are taken out of context. This, of course, is a problem facing any author who can only hope his article will be read in its entirety so that misunderstanding of the intent of the message does not arise.

Drug manufacturing in the United States is unique. For years it has offered more benefits to patients of physicians than in any other country. It has contributed immeasurably to the welfare and economy of people in this nation and elsewhere in the world. It has supported research to the tune of millions of dollars, the exact amount never

First Page Preview View Large
First page PDF preview
First page PDF preview